Abstract: The present invention provides for a method of producing a polysaccharide gel comprising: (a) culturing or growing a cyanobacterium or a mixture of cyanobacteria species in a medium under conditions such that the cyanobacterium or the mixture of cyanobacteria species produces a polysaccharide or a mixture of polysaccharides, (b) optionally separating the polysaccharide or the mixture of polysaccharides from the medium and/or the cyanobacterium or the mixture of cyanobacteria species, and (c) increasing the pH of the polysaccharide or the mixture of polysaccharides such that the polysaccharide or the mixture of polysaccharides forms a gel.

Abstract: The present invention provides for a method of producing a polysaccharide gel comprising: (a) culturing or growing a cyanobacterium or a mixture of cyanobacteria species in a medium under conditions such that the cyanobacterium or the mixture of cyanobacteria species produces a polysaccharide or a mixture of polysaccharides, (b) optionally separating the polysaccharide or the mixture of polysaccharides from the medium and/or the cyanobacterium or the mixture of cyanobacteria species, and (c) increasing the pH of the polysaccharide or the mixture of polysaccharides such that the polysaccharide or the mixture of polysaccharides forms a gel.

Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers.

Abstract: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A?1-42 monomers.

Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers using acylhydrazide compounds.

Abstract: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A?1-42 monomers.

Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers.

Abstract: Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise.

Abstract: Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.

Abstract: The present invention provides amyloid ? peptide assemblies composed of at least three amyloid ? peptide subunits, wherein at least one of the amyloid ? peptide subunits is an amyloid ? peptide analog. The invention further relates to metal complexes of amyloid ? peptide assemblies and the use of amyloid ? peptide assemblies as vaccines and in the identification of agents that modulate assembly of the amyloid ? peptide subunits.

Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.

Abstract: The present invention relates to methods and compositions utilizing inteins to generated libraries of cyclic peptides in vivo.

Abstract: Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.

Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.

Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.

Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.

Abstract: The present attention is directed to compositions and methods for performing functional assays to determine the physiological role of ubiquitin agents and ubiquitin moieties.

Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.